Diametric Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

Diametric Capital’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,365	Closed	-$257K	–	478
2025 Q4	$257K	Sell	20,365 -27,716	-58%	-$317K	0.07%	319
2025 Q3	$481K	Sell	48,081 -48,081	-50%	-$432K	0.18%	157
2025 Q2	$778K	Buy	96,162 +62,698	+187%	+$473K	0.42%	65
2025 Q1	$280K	Buy	33,464 +1,682	+5%	+$14K	0.33%	107
2024 Q4	$252K	Buy	+31,782	New	+$267K	0.17%	184

Other funds holding AMRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Diametric Capital's AMRX Position: Q1 2026 in Review

Diametric Capital sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 20,365 shares — an estimated $257K sold.

Diametric Capital first reported a position in AMRX in Q4 2024 and held it in 5 quarters. The position peaked at $778K in Q2 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

Diametric Capital reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Diametric Capital sold 20,365 Amneal Pharmaceuticals shares in Q1 2026, an estimated $257K.
Diametric Capital first reported a position in Amneal Pharmaceuticals in Q4 2024 and held it in 5 quarters.
Diametric Capital's Amneal Pharmaceuticals position peaked at $778K in Q2 2025.
315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.